Unicycive Therapeutics Inc (NASDAQ: UNCY) kicked off on Monday, up 4.63% from the previous trading day, before settling in for the closing price of $0.35. Over the past 52 weeks, UNCY has traded in a range of $0.20-$1.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -5.80%. While this was happening, its average annual earnings per share was recorded 42.97%. With a float of $83.54 million, this company’s outstanding shares have now reached $94.36 million.
Let’s determine the extent of company efficiency that accounts for 14 employees. In terms of profitability, gross margin is 264.21%, operating margin of 10647.97%, and the pretax margin is 8601.85%.
Unicycive Therapeutics Inc (UNCY) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Unicycive Therapeutics Inc is 11.47%, while institutional ownership is 26.72%.
Unicycive Therapeutics Inc (UNCY) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.13 earnings per share (EPS), lower than consensus estimate (set at -0.12) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.97% per share during the next fiscal year.
Unicycive Therapeutics Inc (NASDAQ: UNCY) Trading Performance Indicators
Take a look at Unicycive Therapeutics Inc’s (UNCY) current performance indicators. Last quarter, stock had a quick ratio of 3.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Unicycive Therapeutics Inc (UNCY)
Looking closely at Unicycive Therapeutics Inc (NASDAQ: UNCY), its last 5-days average volume was 1.92 million, which is a jump from its year-to-date volume of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 71.56%. Additionally, its Average True Range was 0.04.
During the past 100 days, Unicycive Therapeutics Inc’s (UNCY) raw stochastic average was set at 15.50%, which indicates a significant decrease from 70.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.93% in the past 14 days, which was lower than the 132.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4016, while its 200-day Moving Average is $0.8572. However, in the short run, Unicycive Therapeutics Inc’s stock first resistance to watch stands at $0.3897. Second resistance stands at $0.4089. The third major resistance level sits at $0.4290. If the price goes on to break the first support level at $0.3504, it is likely to go to the next support level at $0.3303. Now, if the price goes above the second support level, the third support stands at $0.3111.
Unicycive Therapeutics Inc (NASDAQ: UNCY) Key Stats
The company with the Market Capitalisation of 34.96 million has total of 37,607K Shares Outstanding. Its annual sales at the moment are 680 K in contrast with the sum of -30,540 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was 9,860 K.
